WEX Pharmaceuticals Inc. (“WEX” or the “Company”) is a private biopharmaceutical company based in Vancouver, Canada, developing a new class of non-opioid analgesics. WEX’s proprietary platform and the lead product is Halneuron®. The active pharmaceutical ingredient in Halneuron is Tetrodotoxin (“TTX”) which is a proven sodium channel blocker.
Halneuron is in Phase III clinical development for the treatment of cancer-related pain and will commence Phase III clinical development for chemotherapy-induced neuropathic pain. WEX has conducted over 15 clinical trials with TTX and has treated more than 700 people to date.
WEX is a wholly-owned subsidiary of CK Life Sciences Int’l., (Holdings) Inc. (“CKLS”), listed on the Hong Kong Stock Exchange (stock code: 0775). CKLS is engaged in the business of research and development, manufacturing, commercialization, marketing and selling of environmental and human health products. CKLS is a member of CK Hutchison Group. For additional information, please visit www.ck-lifesciences.com.
Led With Technical Expertise
WEX is led by executives with a strong technical background in pharmaceuticals and life sciences.
Dolor Set Imet
WEX is developing a new class of non-opioid analgesics. The Company’s proprietary platform is Halneuron® (TTX), a highly selective sodium channel blocker. WEX’s lead product Halneuron® based on TTX is in Phase III clinical development for the treatment of cancer related pain and starting Phase III for chemotherapy induced neuropathic pain.
WEX is a subsidiary of CK Life Sciences Int’l., (Holdings) Inc. (“CKLS”), listed on The Stock Exchange of Hong Kong Limited (stock code: 0775). CKLS is engaged in the business of research and development, manufacturing, commercialization, marketing and selling of environmental and human health products, and water businesses and investment in various financial and investment products. CKLS is a member of the CK Hutchison Group.
Led With Technical Expertise
Our Leadership Team
Chief Executive Officer
Mr. Korz has over 40 years of multi-disciplinary life sciences experience gained in public healthcare and holding senior management positions with several emerging and established life sciences companies. Mr. Korz has a broad drug development background with significant experience in business development, clinical development, regulatory affairs and project outsourcing.
Mr. Korz has been with WEX since 2009 as the Director of Clinical Development, and then the Chief Operating Officer, where has advanced TTX through several clinical studies. Prior to WEX, Mr. Korz held senior and executive roles in the biotech industry as Vice President, Drug Development and then President and CEO of Chemokine Therapeutics Corp. Mr. Korz has also held senior clinical positions at Angiotech Pharmaceuticals Inc., AtlaRex Corp., and Biomira Research where he directed and has been responsible for systemic therapy programs in oncology, rheumatoid arthritis, psoriasis, and one of Canada’s largest multiple sclerosis clinical trials.
Mr. Korz is a graduate from Southern Alberta Institute of Technology, and the University of Saskatchewan, and has a Masters of Business Administration from Athabasca University.
Abner Yong, CPA, CA, ACG
Chief Financial Officer
Abner joined WEX Pharmaceuticals Inc. in 2018 and has over 18 years of accounting, corporate finance, treasury and transactions experience gained in an investment-grade multinational company and a Big 4 accounting firm. Prior to WEX, Abner held senior finance roles at Methanex Corporation, a Vancouver based NASDAQ/TSX listed multinational chemicals manufacturer and distributor, in corporate treasury, and corporate accounting where he was responsible for financial operations, global budgeting, debt and credit financings, global treasury, compliance, and financial talent development. Prior to Methanex, Abner was with Ernst & Young in Transactions Advisory Services where he was engaged in debt and credit financings, corporate restructurings, and corporate transactions across Canada. Abner is a CPA with CPA Canada and CPA Australia, and an ACG with the Chartered Governance Institute of Canada. Abner holds a Bachelor of Commerce (Accounting & Finance), and a Post Graduate Diploma in Advanced Accounting from Monash University, Australia.
Dr. Meng Zhou
Vice President, Manufacturing
Dr. Meng Zhou joined WEX as Vice President of Manufacturing in July 2018. Dr. Zhou has over 20 years of pharmaceutical industry experience in drug delivery, formulation development, analytical chemistry, natural product research, clinical trial supply manufacturing, process scale-up and commercialization. At WEX, Dr. Zhou is responsible for CMC, advancing the technology to late phase clinical studies, and securing a complex global supply chain. Prior to WEX, Meng worked with a variety of Big Pharma, Specialty Pharma, and CDMOs. From 2016 to 2018, Meng served as Senior Director of R&D at SteriMax Inc. and specialized in injectable product development. From 2011 to 2016, Meng directed the PDS group in Contract Pharmaceutical Limited (CPL) to support numerous NDA, ANDA and 505(b)2 projects from a global client base. Prior to CPL, Meng held research scientist positions at Patheon Inc., Endo Pharmaceuticals, and ALZA Corporation, a J&J Company. Meng earned his Ph.D. in Pharmaceutical Science from the University of Georgia in 2001, MS in Technology Management from Steven Institute of Technology in 2007, and BS in Medicinal Chemistry from Beijing Medical University in 1997.